Insights
Find the latest news and insights from TrueShares below.
AI’s Most Valuable Application Yet
Advancements in AI and deep learning technologies aren’t just powering chatbots and virtual assistants. Sophisticated models are being utilized within the biomedical industry to tackle some of the most prolific diseases of our time. But these models aren’t just being used by drug makers. Everyone along the chain of discovery, from research and discovery to disease identification and treatment are leveraging AI. Patients themselves may one day be able to hold diagnostic tools in their hands. AI can therefore make healthcare more accessible, more personalized, and more empowering. It can ultimately help save more lives.
Before certain drugs can even be conceived, researchers are creating complex AI models to discover and create their foundational biological ingredients. Researchers at the University of Washington’s Institute for Protein Design (IPD), for example, have used AI to design their own antibodies from scratch.1 The breakthrough took what was a long and expensive process of immunizing animals in the hope it would produce a useful antibody, and evolved it into a faster, more efficient, more cost-effective, and more accurate step toward treating disease.
Also on the discovery side, one private company, Basecamp Research, collaborated with researchers at the University of Pennsylvania to identify a suite of small proteins that kill harmful bacteria.2 This innovative use of advanced AI models can help overcome drug resistance, particularly in the fight against “superbugs.” Such AI-enabled therapies may some day be used to fight or even prevent the next global pandemic.
Cancer is, of course, one of the most vexing plagues, killing roughly 10 million people every year. A class of evolutionary AI models developed by NVIDIA is being harnessed by Basecamp Research to explore gene insertion therapies that can kill cancer cells when integrated directly within human cells. The therapies have killed over 90% of tumor cells in the lab.
AI models are also being used not just to treat cancer, but to identify it earlier and more accurately so patients have a higher chance of fighting it. An international, inter-institutional collaboration of researchers has created a deep learning model to improve skin cancer diagnosis. Results show 94.5% accuracy, which outperforms the common diagnostic tools used widely today.3
And then we come to drug discovery, where AI is being utilized for faster, more efficient, and more personalized drug candidacy than ever before. Researchers in China have recently introduced a novel approach to drug discovery that leverages multi-channel deep learning.4 Their approach represents the latest method of speeding up the drug discovery process, which ultimately makes treating diseases more efficient and cost-effective, and therefore more worth pursuing.
The biomedical industry’s use of AI is a prime example of how AI can benefit society from multiple angles. The quicker researchers can identify diseases and discover their treatments, the healthier our society becomes. Beyond its intrinsic value, AI brings enormous economic value to the biomedical industry.
In a time when concerns over an AI bubble persist, the value AI brings to many sectors of the health sciences serves as a clear example that AI is already delivering on its promises. Sometimes in ways even the researchers themselves never thought possible in their lifetime. The most exciting realization is that AI’s ability to heal us is only just getting started.
---
TrueShares Technology, AI & Deep Learning ETF (LRNZ) seeks to provide thematic exposure to a concentrated portfolio of technology companies that are significantly involved in the application of advanced levels of artificial intelligence within their businesses. LRNZ generally holds 20-30 positions representing companies we believe possess innovative AI and Deep Learning solutions that represent a distinct competitive advantage in a particular industry. A focus on secular growth companies helps lower correlation to broad market indices. LRNZ is led by a portfolio manager with a deep understanding of the technology sector and an ability to conduct extensive qualitative fundamental research.
Learn more here: https://www.true-shares.com/etf/lrnz
---
- https://www.geekwire.com/2025/nobel-winners-lab-notches-another-breakthrough-ai-designed-antibodies-that-hit-their-targets/
- https://www.prnewswire.com/news-releases/basecamp-research-launches-world-first-ai-models-for-programmable-gene-insertion-302657979.html
- http://medicalxpress.com/news/2025-11-deep-skin-cancer-accuracy.html
- https://bioengineer.org/revolutionizing-drug-target-interaction-predictions-with-deep-learning/
.jpg)
Thought Leadership,
Straight to Your Inbox
Disclosures
©2026, TrueShares, ©2026 TrueMark Investments, LLC. (“TrueMark”).
Before investing, carefully consider the TrueShares ETFs investment objectives, risks, charges and expenses. Specific information about TrueShares is contained in the prospectus and a summary prospectus, copies of which may be obtained by visiting www.www.true-shares.com. Read the prospectus carefully before you invest.
An investment in TrueShares is subject to numerous risks, including possible loss of principal. The ETFs are subject to the following principal risks: Authorized Participants, Market Makers, and Liquidity Providers Concentration Risk associated with ETFs; Equity Market Risk; Management Risk; Market Capitalization Risk (Large Cap; Mid Cap, Small Cap Stock); Market Risk; New Fund Risk: The Fund is a recently organized, non-diversified management investment company with no operating history. As a result, prospective investors have no track record or history on which to base their investment decision. Additionally, the Adviser has not previously managed a registered fund, which may increase the risks of investing in the Fund.
Depositary Receipts Risk. American Depositary Receipts (“ADRs”) have risks similar to those of foreign securities (political and economic conditions, changes in the exchange rates, etc.) and entitle the holder to all dividends and capital gains that are paid out on the underlying foreign shares.
Individual investors should contact their financial advisor or broker dealer representative for more information on TrueShares ETFs.
Investment Products and Services are: NOT FDIC INSURED / MAY LOSE VALUE / NO BANK GUARANTEE.
All registered investment companies, including TrueShares, are obliged to distribute portfolio gains to shareholders at year-end regardless of performance. Trading in TrueShares ETFs will also generate tax consequences and transaction expenses. The information provided is not intended to be tax advice. Tax consequences of dividend distributions may vary by individual taxpayer.
TrueShares ETFs are bought and sold through exchange trading at market price, not Net Asset Value (NAV), and are not individually redeemed from the fund. Shares may trade at a premium or discount to their NAV in the secondary market. Brokerage commissions will reduce returns.
ETF shares may be bought or sold throughout the day at their market price, not their NAV, on the exchange on which they are listed. Shares of ETFs are tradable on secondary markets and may trade either at a premium or a discount to their NAV on the secondary market. ETFs trade like stocks, fluctuate in market value and may trade at prices above or below the ETF’s NAV. Brokerage commissions and ETF expenses will reduce returns.
Fund Intelligence Mutual Fund Industry and ETF Award shortlists and winners are comprised of individuals and firms who have submitted entries or been nominated via the online submission process, as well as through recommendations from leading market participants. Fund Intelligence Mutual Fund Industry and ETF Award judges will use the submitted application material, as well as any uploaded supplemental information, to determine which firm, individual or product they believe to be the most suitable and deserving winners for each category. Fund Intelligence Mutual Fund Industry and ETF Award judges have the discretionary power to move nominations into alternative categories that they think may be more suitable. Fund Intelligence Mutual Fund Industry and ETF Awards were decided by an independent panel of 20 judges with expertise across the asset management space.
TrueShares ETFs (the “Funds”) are registered with the United States Securities and Exchange Commission under the Investment Company Act of 1940. The fund is distributed by Paralel Distributors LLC, Member FINRA. Paralel is not affiliated with TrueMark Investments, LLC. TrueMark Investments, LLC, is the investment advisor to the Funds and receives a fee from the Funds for its services.
TrueMark Investments, LLC is the investment advisor to the Funds and receives a fee from the Funds for its services.
TrueShares ETFs are offered only to United States residents, and information on this site is intended only for such persons. Nothing on this website should be considered a solicitation to buy nor an offer to sell shares of any fund in any jurisdiction where the offer or solicitation would be unlawful under the securities laws of such jurisdiction.